The Global Allergy Diagnostics Market boasts a total value of $4.8 billion in 2021 and is projected to register a growth rate of 11.1% to reach a value of $8.2 billion by 2026. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, increasing funds by organizations in allergy diagnostics are anticipated to drive growth of the global market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701
Market Dynamics
DRIVER: Rising environmental pollution levels
Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors causing chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas due to the higher exposure to environmental pollutants in cities (as a result of vehicular pollution and industrial activities).
As per the WHO, more than 80% of people living in urban areas are exposed to air quality levels that exceed the WHO safety limits; though this is a global trend, its effects are more severe in the urban areas of low-income countries. This is a major indicator for the growth of the allergy diagnostics market, as air pollution from motor vehicles has been indicated as one of the major risk factors responsible for allergic diseases.
OPPORTUNITY: Use of mHealth in allergy diagnosis
The use of mHealth for the diagnosis of rhinitis is currently limited, with a small number of mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.
Restraints: Premium costs associated with allergy diagnostic instruments
Several allergy diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are periodically updated by market players. As these instruments are equipped with advanced features and functionalities, they are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT). For instance, immunoassay analyzers cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. Semi-automated ELISA readers cost between USD 2,000 and USD 5,000, while fully automated analyzers cost around USD 14,000. Furthermore, maintenance and insurance, laboratory supervision, and overheads (including utilities, space, and administration) are additional expenses required to operate this equipment.
Trends: Reagent rental agreements
Reagent rental agreements are sales agreements between end users (such as hospitals and diagnostic laboratories) and allergy diagnostic product manufacturers. Under these agreements, the end user rents or purchases instruments at a subsidized rate by entering into a reagent-purchase contract with the manufacturer. This mutually beneficial agreement lowers the initial capital investment for the end user while assuring the manufacturer of purchases over a substantial time period. In some cases, analyzers are rented out to the end user at a cost-per-test rate.
Request Free Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=232871701
“Consumables are expected to hold the largest share of the allergy diagnostics market, by product & service.”
Based on product & service, the global market is segmented into consumables, instruments, and services. The consumables segment accounted for the largest share of the global market. The large share of the consumables segment can be attributed to the rising cases of allergies and the requirement for rapid tests to diagnose allergic conditions. The segment is also anticipated to witness significant growth during the forecast period.
“In vivo tests are expected to hold the largest share of the allergy diagnostics market, by test type.”
Based on test type, the global market is segmented into in vivo tests and in vitro tests. The in vivo tests segment accounted for the largest share of this market. The growth of this segment is mainly driven by the increased adoption of various in vivo tests, such as skin prick tests. These tests are reliable, safe, convenient, and cost-effective, as compared to their conterparts, the in vitro tests.
“Inhaled allergens are expected to hold the largest share of the allergy diagnostics industry, by an allergen.”
Based on allergens, the global market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. The inhaled allergens segment accounted for the largest share of This market due to the rising environmental pollution levels and rising pollen coupled with other factors such as mold, fungus, and dust.
“Diagnostic laboratories are expected to hold the largest share of the allergy diagnostics market, by end user in 2021.”
Based on end user, the global market is segmented into diagnostic laboratories, hospital-based laboratories, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the market. The large share of the segment can be primarily attributed to the preference for proper diagnosis from a specialist, rising awareness regarding the management of allergic diseases, and the availability of funds for the operation of independent diagnostic laboratories.
“North America commanded the largest share of the allergy diagnostics industry in 2021.”
Based on region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of this market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.
Key Market Players:
Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).
Report Objectives
- To define, describe, and forecast the allergy diagnostics market based on product & service, allergen, test type, end user, and region.
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, trends, opportunities, and challenges, and COVID-19 Impact Analysis)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall allergy diagnostics market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
- To track and analyse competitive developments such as product launches, deals and expansions in the allergy diagnostics market.
Buy Now:
https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=232871701
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/allergy-diagnostics-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/allergy-diagnostics.asp
